Gilead Sciences and its subsidiary Dodgers Merger Sub plan to acquire Kite Pharma for $11.9bn.
Both the acquirer and target companies are biopharmaceutical companies based in the US.
The acquisition will enable Gilead Sciences to expand its presence in the oncology and cell therapy areas, while also enabling Kite Pharma to progress the development of its pipeline.
Clinical-stage biotechnology company RegenxBio plans to acquire rare disease company Dimension Therapeutics.
The acquisition will be made by RegenxBio’s wholly owned subsidiary Muddy Charles Acquisition Corporation (Merger Sub) and enhance Regenxbio’s gene therapy product pipeline.
All companies involved in the acquisition are based in the US.